Bevacizumab for Recurrent Malignant Glioma

* INCLUSION CRITERIA: * Patients with histologically proven intracranial malignant glioma will be eligible for this protocol. * Malignant glioma include glioblastoma multiforme (GBM), * gliosarcoma, * anaplastic astrocytoma (AA), * anaplastic oligodendroglioma (AO), * anaplastic mixed oligoastrocytoma (AMO), * or malignant astrocytoma NOS (not otherwise specified). * Patients must have evidence for tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan. * This scan should be performed within 14 days prior to registration and on a fixed dose of steroids for at least 5 days. * If the steroid dose is increased between the date of imaging and registration a new baseline MR/CT is required. * The same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement. * Patients having undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply: * They have recovered from the effects of surgery. * Residual disease following resection of recurrent tumor is not mandated for eligibility into the study. * To best assess the extent of residual disease post-operatively, a CT/ MRI should be done: * no later than 96 hours in the immediate post-operative period or * at least 4 weeks post-operatively, and * within 14 days of registration, and * on a steroid dosage that has been stable for at least 5 days. * If the 96 hour scan is more than 21 days before registration, the scan needs to be repeated. * If the steroid dose is increased between the date of imaging and registration, a new baseline MRI/CT is required on a stable steroid dosage for at least 5 days. * Patients must have progressed after radiation therapy and must have an interval of greater than or equal to 4 weeks from the completion of radiation therapy to study entry. * All patients must sign an informed consent indicating that they are aware of the investigational nature of this study. * Patients must be greater than or equal to 18 years old, * and with a life expectancy greater than 8 weeks. * Patients must have a Karnofsky performance status of greater than or equal to 60. * Patients must have recovered from the toxic effects of prior therapy: * 2 weeks from any investigational agent, * 4 weeks from prior cytotoxic therapy, * two weeks from vincristine, * 6 weeks from nitrosoureas, * 3 weeks from procarbazine administration, * and 1 week for non-cytotoxic agents, e.g., interferon, * tamoxifen, * thalidomide, * cis-retinoic acid, etc. (radiosensitizer does not count). * Any questions related to the definition of non-cytotoxic agents should be directed to the Study Chair. * Patients must have adequate bone marrow function (white blood count (WBC) -greater than or equal to 3,000/microliters, * absolute neutrophil count (ANC) greater than or equal to 1,500/mm\^3, * platelet count of greater than or equal to 100,000/mm\^3, * and hemoglobin greater than or equal to 10 gm/dl), * adequate liver function (serum glutamic oxaloacetic transaminase (SGOT) and -bilirubin less than 2 times upper limit of normal (ULN)), * and adequate renal function (creatinine less than 1.5 mg/dL and/or creatinine -clearance greater than or equal to 60 cc/min) before starting therapy. * These tests must be performed within 14 days prior to registration. -Eligibility level for hemoglobin may be reached by transfusion. * Patients must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patients' ability to tolerate this therapy * This study was designed to include women and minorities, but was not designed to measure differences of intervention effects. * Males and females will be recruited with no preference to gender. * No exclusion to this study will be based on race. * Minorities will actively be recruited to participate. * Urine protein should be screened by dipstick or urine analysis for Urine Protein Creatinine (UPC) ratio. * For proteinuria greater than or equal to 1+ or urine protein: * creatinine UPC ratio greater than 1.0, * 24-hour urine protein should be obtained and the level should be less than 1000 mg for patient enrollment. * Patients must practice adequate contraception EXCLUSION CRITERIA: * Patients who, in the view of the treating physician, * have significant active cardiac, * hepatic, * renal, * or psychiatric diseases are ineligible. * No concurrent use of other standard chemotherapeutics or investigative agents. * Patients known to have a malignancy that has required treatment in the last 12 months and/or is expected to require treatment in the next 12 months (except non-melanoma skin cancer or carcinoma in-situ in the cervix). * Patients who have an active infection. * Pregnant (positive pregnancy test) or nursing women. * Both fertile men and women must agree to use adequate contraceptive measures during study therapy and for at least 6 months after the completion of bevacizumab therapy. * Patients who have any disease that will obscure toxicity. * Patients with evidence of acute intracranial/intratumoral hemorrhage on pre-study CT scan. * Concurrent anti-coagulation or anti-platelet medication (including aspirin, -non-steroidal anti-inflammatories, * cyclooxygenase 2 (COX-2) inhibitors). * Serious or non-healing wound, * ulcer * or bone fracture * History of abdominal fistula, * gastrointestinal perforation * or intra-abdominal abscess within 28 days * Invasive procedures defined as follows: * Major surgical procedure, * open biopsy * or significant traumatic injury within 28 days prior to Day 1 therapy * Anticipation of need for major surgical procedures during the course of the study * Core biopsy within 7 days prior to day 1 (D1) therapy * Patients with clinically significant cardiovascular disease * History of cerebrovascular accident (CVA) within 6 months * Uncontrolled hypertension (greater than 150/100 mmHg) * Myocardial infarction or unstable angina within 6 months * New York Heart Association grade II or greater congestive heart failure * Serious cardiac arrhythmia requiring medication * Unstable angina pectoris * Clinically significant peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Prothrombin time (PT) international normalized ratio (INR) greater than 1.5 * Patients with known hypersensitivity of Chinese hamster ovary cell products or other recombinant human antibodies